LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

• DOI: 10.1016/j.annonc.2022.04.453
• Publication Date: 2022-07-02T11:31:26Z
• Authors: A. Bullock; J. Grossman; M. Fakih; H. Lenz; M. Gordon; K. Margolin; B. Wilky; D. Mahadevan; J. Trent; B. Bockorny; J. Moser; A. Balmanoukian; B. Schlechter; W. Ortuzar Feliu; K. Rosenthal; B. Bullock; J. Stebbing; J. Godwin; S. O'Day; A. Tsimberidou; A. El-Khoueiry
• Keywords: 03 medical and health sciences; 0302 clinical medicine